Primary care considerations in the management of Inflammatory Bowel Disease patients

Practical Gastroenterology

Volumn 36, Issue 4, 2012, Pages 48-54

  Manten, Emory ^a   Green, Jesse A ^a   Bartholomew, Catherine ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; AZATHIOPRINE; COLESTYRAMINE; CORTICOSTEROID; FENTANYL; FUROSEMIDE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; INFLIXIMAB; INSULIN GLARGINE; ISOPHANE INSULIN; LISINOPRIL; MERCAPTOPURINE; MESALAZINE; METFORMIN; METHOTREXATE; NAPROXEN; PERCOCET; PIOGLITAZONE; PREDNISONE; ROSIGLITAZONE; SALBUTAMOL; SALMETEROL; SIMVASTATIN; THEOPHYLLINE; TRAMADOL;

ANEMIA; APLASTIC ANEMIA; ARTICLE; ASTHMA; BONE MARROW SUPPRESSION; CHILL; CREATININE BLOOD LEVEL; DATA BASE; DIABETES MELLITUS; DIARRHEA; DYSLIPIDEMIA; ENTERITIS; FACE EDEMA; FEVER; HEADACHE; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; KIDNEY FAILURE; LACTIC ACIDOSIS; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; MEDLINE; MYALGIA; NAUSEA; PAIN; PANCREATITIS; PERICARDITIS; RASH; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

EID: 84863817670     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126 (6):1504.
2. Egan BM, Zhao Y, Axon, RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043.
3. Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884
4. http://www.cdc.gov/diabetes/statistics/incidence/fig2.htm Data Source: Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Division of Health Interview Statistics, data from the National Health Interview Survey. Data computed by personnel in CDC's Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion.
5. McCulloch, David K., Robertson R Paul. Risk factors for type 2 diabetes mellitus. In: UpToDate, Nathan, DM (ED), UpToDate, Waltham, Ma 2012.
6. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 1998;97(10):946.
7. Rosenson, Ronald S. ATP III guidelines for treatment of high blood cholesterol. In: UpToDate, Freeman, MW (ED), UpToDate, Waltham, Ma 2012.
8. Bajwa, Zahid H., Smith, Howard S. Overview of the treatment of chronic pain, In: UpToDate Aronson, MD(ED), UpToDate, Waltham, Ma 2012.
9. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA. 1998; 280(2):147.
10. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. Nov; 23(5):429-48
11. Baumgart DC, Pintoffl JP, Strum A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. AM J Gastroenterology. 2005May;101(5):1048-56
12. Yorulmaz E, Adali G, Yorulmaz H, Ulasoglu C, Tasan G, Tuncer I. Metabolic syndrome frequency in inflammatory bowel disease. Saudi J Gastroenterology. 2011 Nov-Dec; 17(6):376-82
13. Prince A, Whelan K, Moosa A, Lomer MC, Reidlinger DP. Nutritional Problems in inflammatory bowel disease: the patient perspective. J Crohns Colitis. 2011 Oct; 5(5):443-50;Epub 2011 May 25
14. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD Genetics: common pathways with other diseases. GUT. 2011 Dec;60(12):1739-53. Epub 2011 Feb 7.
15. Cohen R, Robinson D Jr., Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflammatory Bowel Disease Jun;14(6):738-43
16. Sappati Biyyani RS, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol. 2010 Nov-Dec; 4(6):478-82. Epub 2010 Oct 28.
17. Edwards JT, Radford-Smith GL, Florin TH. Chronic Narcotic Use in Inflammatory Bowel Disease Patients: Prevelance and Clinical Characteristics. J Gastroenterology Hepatology. 2001 Nov; 16(11):1235-1238.
18. 2010 Adult Asthma Data: Prevalence Tables and Maps. http:// www.cdc.gov/asthma/brfss/2010/lifetime/tableL1.htm
19. Wahed M, Goodhand JR, West O, McDermott A, Hajek P, Rampton DS. Tobacco Dependence and awareness of health risks of smoking in patients with inflammatory bowel disease. Eur J Gastroenterology Hepatology. 2011 Jan;23(1)90-94.
20. Fenta YA, Tello N, Junj JA, Urm SH, Loftus EV Jr, Yawn BP, Li X, Juhn YJ. Inflammatory Bowel Disease and Asthma: A population based, case control study. Inflamm Bowel Dis. 2010 Nov: 16(11):1957-62